Share price · IONS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IONS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026-9.1%
- 9 Nov 2026-21.4%
- 9 Jul 2026-23.9%
- 29 Apr 2026+4.2%
- 5 Mar 2026-5.4%
Nothing announced by IONS that day or the session before.
- 25 Feb 2026-5.3%
Share of unusual movement by asset
For each asset, the share of IONS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(20 total)
| Target & Modality | |||
|---|---|---|---|
Donidalorsen(Dawnzera) | Approved | Prekallikrein (PKK) mRNARNA / oligonucleotide | Hereditary Angioedema |
Eplontersen(Wainua) | Approved | Transthyretin (TTR)RNA / oligonucleotide | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy |
Nusinersen(Spinraza) | Approved | SMN2 pre-mRNARNA / oligonucleotide | Spinal Muscular Atrophy |
Olezarsen(Tryngolza) | Approved | APOC3RNA / oligonucleotide | Familial Chylomicronemia SyndromeSevere HypertriglyceridemiaCardiovascular Disease / Dyslipidemia Hypertriglyceridemia |
Tofersen(Qalsody) | Approved | SOD1RNA / oligonucleotide | Amyotrophic Lateral Sclerosis |
Zilganersen(Zanvastro) | Approved | GFAP pre-mRNARNA / oligonucleotide | Alexander Disease |
Inotersen(Tegsedi) | US approval withdrawn | Transthyretin (TTR)RNA / oligonucleotide | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Polyneuropathy |
| Phase 3 | SCN2A (antisense knockdown)RNA / oligonucleotide | Epilepsy | |
| Phase 3 | UBE3A-ATS (UBE3A antisense transcript)RNA / oligonucleotide | Angelman Syndrome | |
| Phase 3 | Apolipoprotein(a) mRNARNA / oligonucleotide | Atherosclerotic Cardiovascular Disease | |
| Phase 3 | Complement factor B (CFB)RNA / oligonucleotide | IgA Nephropathy | |
| Phase 3 | FUSRNA / oligonucleotide | Amyotrophic Lateral Sclerosis | |
| Phase 3 | APOC3 mRNARNA / oligonucleotide | Familial Chylomicronemia SyndromeSevere Hypertriglyceridemia | |
| Phase 2 | STAT3 antisense oligonucleotideRNA / oligonucleotide | Non-Small Cell Lung Cancer | |
| Phase 2 | MAPT mRNA (RNAi/ASO)RNA / oligonucleotide | Alzheimer's Disease |
Upcoming events
(22 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (6)
March 2027 (1)
What to watch
June 2027 (1)
What to watch
August 2027 (2)
2028 (4)
February 2028 (2)
2029 (3)
2030 (5)
January 2030 (1)
What to watch
March 2030 (1)
What to watch
August 2030 (1)
What to watch
December 2030 (2)
What to watch
2032 (1)
March 2032 (1)
What to watch
Regulatory and conference events
(20)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
The 12 most recent of 20 past events are shown.
Financial reports
Quarterly & interim (21)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $243M | — | $296M+ $1.6B short-term inv. | $110M-$179M operating cash flow | report ↗ |
View 20 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $268M | — | $350M+ $1.7B short-term inv. | $115M$566M operating cash flow | report ↗ |
| 2026-Q1 | $246M | — | $173M+ $1.7B short-term inv. | $93M-$793M operating cash flow | report ↗ |
| 2025-Q4 | — | — | $372M+ $2.3B short-term inv. | $229M-$138M operating cash flow | report ↗ |
| 2025-Q3 | $157M | — | $338M+ $1.9B short-term inv. | $129M-$131M operating cash flow | report ↗ |
| 2025-Q2 | $452M | — | $297M+ $2.0B short-term inv. | —$151M operating cash flow | report ↗ |
| 2025-Q1 | $132M | — | $264M+ $1.9B short-term inv. | $147M-$151M operating cash flow | report ↗ |
| 2024-Q4 | — | — | $242M+ $2.1B short-term inv. | $104M-$116M operating cash flow | report ↗ |
| 2024-Q3 | $134M | — | $335M+ $2.1B short-term inv. | $140M-$115M operating cash flow | report ↗ |
| 2024-Q2 | $225M | — | $294M+ $1.8B short-term inv. | $66M-$120M operating cash flow | report ↗ |
| 2024-Q1 | $120M | — | $349M+ $1.9B short-term inv. | $143M-$150M operating cash flow | report ↗ |
| 2023-Q4 | — | — | $399M+ $1.9B short-term inv. | $9.3M$33M operating cash flow | report ↗ |
| 2023-Q3 | $144M | — | $352M+ $1.9B short-term inv. | $147M-$109M operating cash flow | report ↗ |
| 2023-Q2 | $188M | — | $425M+ $2.0B short-term inv. | $85M-$97M operating cash flow | report ↗ |
| 2023-Q1 | $131M | — | $309M+ $2.0B short-term inv. | $124M-$134M operating cash flow | report ↗ |
| 2022-Q4 | — | — | $276M+ $1.7B short-term inv. | $52M-$200M operating cash flow | report ↗ |
| 2022-Q3 | $160M | — | $315M+ $1.7B short-term inv. | $47M-$24M operating cash flow | report ↗ |
| 2022-Q2 | $134M | — | $522M+ $1.5B short-term inv. | $105M-$18M operating cash flow | report ↗ |
| 2022-Q1 | $142M | — | $543M+ $1.5B short-term inv. | $65M-$32M operating cash flow | report ↗ |
| 2021-Q4 | — | — | $869M+ $1.2B short-term inv. | —$204M operating cash flow | report ↗ |
| 2021-Q3 | $133M | — | $633M+ $1.4B short-term inv. | $82M-$56M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $944M | $916M | $372M+ $2.3B short-term inv. | $95M-$269M operating cash flow | report ↗ |
Ionis Pharmaceuticals reported full-year 2025 revenue of $943.71M, up 33.8% YoY, and R&D spend of $915.62M, up 1.6% YoY. Cash and equivalents were $372.26M, within total cash, cash equivalents and short-term investments of $2.7 billion, and the company reported a net loss of $381.39M.
For 2026, Ionis guided to revenue of $800-$825 million, a non-GAAP operating loss of $500-$550 million, and approximately $1.6 billion in cash, cash equivalents and short-term investments. The company highlighted TRYNGOLZA's first-year net product sales of $108 million, the DAWNZERA launch, an sNDA submission for olezarsen in severe hypertriglyceridemia, and an NDA submission for zilganersen in Alexander disease. Pipeline advances included positive Phase 3 B-Well results for bepirovirsen in chronic hepatitis B, with regulatory filings planned, and anticipated Phase 3 readouts for pelacarsen and eplontersen in 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $705M | $902M | $242M+ $2.1B short-term inv. | $113M-$501M operating cash flow | report ↗ |
| 2023-FY | $788M | $900M | $399M+ $1.9B short-term inv. | $92M-$308M operating cash flow | report ↗ |
| 2022-FY | $587M | — | $276M+ $1.7B short-term inv. | $67M-$274M operating cash flow | report ↗ |
| 2021-FY | $810M | $638M | $869M+ $1.2B short-term inv. | $7.2M$31M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($1.2M), 107 sales ($117.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-10 | Hayden Michael R · director | Open-market purchase | 5,000 | $29.64 | $148K | Form 4 |
| 2026-10-16 | Swayze Eric · EVP Research | Open-market sale | 53 | $43.54 | $2K | Form 4 |
| 2026-10-16 | Devers Shannon L. · EVP, Chief Human Resources Ofc | Open-market sale | 1,357 | $43.54 | $59K | Form 4 |
| 2026-10-15 | Swayze Eric · EVP Research | Option exercise | 125 | — | — | Form 4 |
| 2026-10-15 | Devers Shannon L. · EVP, Chief Human Resources Ofc | Option exercise | 2,820 | — | — | Form 4 |
| 2026-10-15 | Swayze Eric · EVP Research | Option exercise (derivative) | 125 | — | — | Form 4 |
| 2026-10-15 | Devers Shannon L. · EVP, Chief Human Resources Ofc | Option exercise (derivative) | 2,820 | — | — | Form 4 |
| 2026-08-31 | Birchler Brian · EVP, Corp and Development Ops | Other (see filing) | 58 | $51.31 | $3K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 490 reporting institutions held 172.6M shares ($12.1B, 103.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 24,556,637 | $1.8B |
| 2 | Capital World Investors | 21,186,369 | $1.6B |
| 3 | BlackRock, Inc. | 10,442,476 | $784.1M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7,808,902 | $586.4M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 7,118,330 | $534.5M |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 6,391,816 | $480.0M |
| 7 | TWO SIGMA INVESTMENTS, LP | 5,857,629 | $439.8M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 3,984,332 | $305.2M |
| 9 | STATE STREET CORP | 3,995,564 | $300.0M |
| 10 | ROYAL BANK OF CANADA | 3,801,815 | $285.5M |
| 11 | JPMORGAN CHASE & CO | 2,363,567 | $171.4M |
| 12 | Tweedy, Browne Co LLC | 2,275,625 | $170.9M |
| 13 | Artisan Partners Limited Partnership | 2,058,308 | $154.6M |
| 14 | BAKER BROS. ADVISORS LP | 2,047,727 | $153.8M |
| 15 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1,979,669 | $148.7M |